[1] American Diabetes Association, “Diagnosis and Classification of Diabetes Mellitus,” Diabetes Care, Vol. 33, No. S1, 2010, pp. S62-S69. doi:10.2337/dc10-S062
[2] B. F. J. Ampudia, “Fallo Celular Beta y Progresión de la Diabetes Mellitus Tipo 2,” Endocrinology and Nutrition, Vol. 50, No. 7, 2003, pp. 274-279.
[3] R. González, E. Buchaca and M. Licea, “Fisiopatología y Progresión de las Personas con,” Revista Cubana de Endocrinología, Vol. 10, No. 1, 2011, pp. 11-17.
[4] UK Prospective Diabetes Study 16, “Overview of 6 Years Therapy of Type II Diabetes: A Progressive Disease. United Kingdom Prospective Diabetes Study Group,” Diabetes, Vol. 45, No. 11, 1996, pp. 1249-1258. doi:10.2337/diabetes.44.11.1249
[5] D. M. Nathan, J. B. Buse, M. B. Davidson, E. Ferrannini, R. R. Holman, R. Sherwin, et al., “Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes,” Diabetes Care, Vol. 32, No. 1, 2009, pp. 193-203. doi:10.2337/dc08-9025
[6] R. Bastarrachea, J. Montero, V. Saavedra, R Cerda, A. Machado and A. Comuzzie, “Objetivos Moleculares Para Dise?ar Nuevos Fármacos Para el Tratamiento de la Diabetes Tipo 2 y la Obesidad,” Revista médica de Chile, Vol. 136, No. 1, 2008, pp. 107-117. doi:10.4067/S0034-98872008000100014
[7] J. L. Evans, I. P. Goldfine, B. A. Maddus and G. M. Grodsky, “Are Oxidative Stress-Activated Signalling Pathways Mediators of Insulin Resistance and Beta-Cell Dysfunction?” Diabetes, Vol. 52, No. 1, 2003, pp. 1-8. doi:10.2337/diabetes.52.1.1
[8] R. Robertson, J. Harmon, P. Oanh and V. Poitout, “Beta Cell Glucose Toxicity, Lipotoxicity and Chronic Oxidative Stress in Type 2 Diabetes,” Diabetes, Vol. 53, No. 1, 2004, pp. S119-S124. doi:10.2337/diabetes.53.2007.S119
[9] G. Orasanu and J. Plutzky, “The Pathologic Continuum of Diabetes Vascular Disease,” Journal of the American College of Cardiology, Vol. 53, No. 5, 2009, pp. S35-S42. doi:10.1016/j.jacc.2008.09.055
[10] Y. Yu and T. J. Lyons, “A Lethal Tread in Diabetes, Hyperglucemia, Dyslipemia, Oxidative Stress and Endothelial Dysfunction,” American Journal of Medical Science, Vol. 330, No. 5, 2005, pp. 227-232. doi:10.1097/00000441-200511000-00005
[11] J. M. Forbes, M. T. Coughlan and M. E. Cooper, “Oxidative Stress as a Major Culprit in Kidney Disease in Diabetes,” Diabetes, Vol. 57, No. 6, 2008, pp. 1446-1454. doi:10.2337/db08-0057
[12] W. Jia, W. Gao and L. Tang, “Antidiabetic Herbal Drugs Offi cially Approved in China,” Phytotherapy Research, Vol. 17, No. 10, 2003, pp. 1127-1134. doi:10.1002/ptr.1398
[13] B. Ludvik, B. Neuffer and G. Pacini, “Efficacy of Ipomea Batatas (Caiapo) Ondiabetes Control in Type 2 Diabetes Subjects Treated with Diet,” Diabetes Care, Vol. 27, No. 2, 2004, pp. 436-440. doi:10.2337/diacare.27.2.436
[14] E. A. Sotoniemi, E. Haapakoski and A. Rautio, “Ginseng Therapy in Non-Insulindependent Diabetic Patients. Effect on Psychophysical Performance, Glucose Homeostasis, Serum Lipids, Serum Aminoterminal-Propeptide Concentration and Body Weight,” Diabetes Care, Vol. 18, No. 10, 1995, pp. 1373-1375.
[15] D. Cheta and F. Trifan, “Diamel Associated with Insulin or ADO or as a Pharmacological Monotherapy,” 2010. http://www.catalysisusa.net/stud_Diamel.html
[16] P. E. Milbury, B. Graf and J. M. C. Celentano, “Bilberry (Vaccinium myrtillus) Anthocyanins Modulate Heme Oxygenase-1 and Glutathione S-Transferasepi Expression in ARPE-19 Cells,” Investigative Ophthalmology and Visual Science, Vol. 48, No. 5, 2007, pp. 2343-2349. doi:10.1167/iovs.06-0452
[17] C. Olvera, G. Leo and H. Hernández, “Páncreas y Células Beta: Mecanismos de Diferenciación, Morfogénesis y Especificación Celular Endocrina. Regeneración?” Boletín Médico del Hospital Infantil de México, Vol. 65, No. 4, 2008, pp. 306-324.
[18] Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group, “Sustained Effect of Intensive Treatment of Type 1 Diabetes Mellitus on Development and Progression of Diabetic Nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study,” The Journal of American Medical Association, Vol. 290, No. 16, 2003, pp. 2159-2167. doi:10.1001/jama.290.16.2159
[19] D. M. Nathan, P. A. Cleary, J. Y. Backlund, S. M. Genuth, J. M. Lachin, T. J. Orchard, et al., “Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes,” New England Journal of Medicine, Vol. 353, No. 25, 2005, pp. 2643-2653. doi:10.1056/NEJMoa052187
[20] S. Colagiuri, C. A. Cull and R. R. Holman, “Are Lower Fasting Plasma Glucose Levels at Diagnosis of Type 2 Diabetes Associated with Improved Outcomes? U.K. Prospective Diabetes Study 61,” Diabetes Care, Vol. 25, No. 8, 2002, pp. 1410-1417. doi:10.2337/diacare.25.8.1410
[21] A. Ceriello, “La ‘Memoria Metabólica’ Inducida por la Hiperglucemia: El Nuevo Reto en la Prevención de la Enfermedad Cardiovascular en la Diabetes,” Revista Espa?ola de Cardiología, Vol. 8, No. SC, 2008, pp. 12-18.
[22] J. A. Arguedas, “Effectividad y Seguridad Comparativa de los Medicamentos Para la Diabetes Tipo 2: Una Actualización Incluyendo Nuevas Drogas y Combinaciones de dos Drogas. Actualización Médica Periódica,” 2011. www.ampmd.com
[23] W. L. Bennett, N. M. Maruthur and S. Singh, “Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations,” Annals of Internal Medicine, Vol. 154, No. 9, 2011, pp. 602-613.
[24] R. Cabrera, “Diamel Intervention Trial on Metabolic Syndrome. AcciMonitor,” 2010. http://www.finlay.sld.cu/publicaciones/vaccimonitor/Vm2010/Abstracts-Pharmacology-2010.pdf
[25] A. Hernández Yero and D. Vargas “Utilidad de Diamel en Pacientes con Diabetes Mellitus Tipo 2 en Tratamiento Combinado con Glibenclamida,” Avances en Diabetología, Vol. 23, No. 1, 2007, pp. 284-290.
[26] S. S. Sheu, D. Nauduri and M. W. Anders, “Targeting Antioxidants to Mitochondria: A New Therapeutic Direction,” Biochimica et Biophysica Acta, Vol. 1762, No. 2, 2006, pp. 256-265. doi:10.1016/j.bbadis.2005.10.007
[27] A. Gómez, E. Hernández, M. González and E. Martínez, “Efecto de la Administración Oral de Zinc Sobre Sensibilidad a la Insulina y Niveles Séricos de Leptina y Andrógenos en Hombres con Obesidad,” Revista médica de Chile, Vol. 134, No. 3, 2006, pp. 279-284.
[28] F. M. Vaz and R. Wanders, “Carnitine Biosynthesis in Mammals,” 2002. http://www.biochemj.org/bj/361/0417/3610417.pdf
[29] E. Trifan and D. Cheta, “Study on Use of Diamel in the Treatment of Diabetes Mellitus,” Nutritie si Boli Metabolic, Vol. 1, No. 1, 2002, pp. 23-38.
[30] E. Shafrir and I. Raz, “Diabetes: Mellitus or Lipidus?” Diabetologia, Vol. 46, No. 3, 2003, pp. 433-440.
[31] R. A. DeFronzo, “Insulin Resistance, Lipotoxicity, Type 2 Diabetes and Atherosclerosis: The Missing Links. The Claude Bernard Lecture 2009,” Diabetologia, Vol. 53, No. 7, 2010, pp. 1270-1287. doi:10.1007/s00125-010-1684-1
[32] R. Hernando, “Etiología y Fisiopatología de la Diabetes Mellitus Tipo 2,” Revista México de Cardiology, Vol. 22, No. 1, 2011, 5 p. www.medigraphic.com/revmexcardio